PMHNP BOARD REVIEW & CLINICAL COMPETENCY
EXAMINATION
Advanced Psychopharmacology, Neurobiology, and Clinical
Management of Generalized Anxiety Disorder, Panic Attacks, and
Selective Serotonin Reuptake Inhibitors (Sertraline)
200 Comprehensive Questions with Detailed Rationales
Module 1: Neurobiology and Receptor Occupancy of SSRIs
(Sertraline)
Question 1: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 1: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
,Question 2: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 2: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
Question 3: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 3: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
, D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
Question 4: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 4: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
Question 5: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 5: Which specific
neurobiological transporter mechanism primarily mediates the
, therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
Question 6: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 6: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
EXAMINATION
Advanced Psychopharmacology, Neurobiology, and Clinical
Management of Generalized Anxiety Disorder, Panic Attacks, and
Selective Serotonin Reuptake Inhibitors (Sertraline)
200 Comprehensive Questions with Detailed Rationales
Module 1: Neurobiology and Receptor Occupancy of SSRIs
(Sertraline)
Question 1: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 1: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
,Question 2: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 2: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
Question 3: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 3: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
, D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
Question 4: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 4: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
Question 5: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 5: Which specific
neurobiological transporter mechanism primarily mediates the
, therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
(SSRI) that exerts its primary antidepressant and anxiolytic effects by
binding to the primary high-affinity site on the presynaptic serotonin
transporter (SERT), blocking serotonin reuptake and thereby
enhancing serotonergic neurotransmission across synaptic clefts.
Question 6: A 28-year-old female presenting with severe GAD and
panic attacks initiates sertraline. Question 6: Which specific
neurobiological transporter mechanism primarily mediates the
therapeutic action of sertraline at the synaptic cleft during initial
receptor occupancy phases?
A. Selective antagonism of central postsynaptic 5-HT2A receptors.
B. Inhibition of the presynaptic serotonin transporter (SERT),
preventing reuptake and increasing synaptic 5-HT availability.
C. Direct agonism at presynaptic 5-HT1A autoreceptors to decrease
overall serotonergic tone.
D. Inhibition of monoamine oxidase A (MAO-A) leading to reduced
enzymatic degradation of norepinephrine and dopamine.
Correct Answer: B
Rationale: Sertraline is a selective serotonin reuptake inhibitor
